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Dominant Mutation of CCDC78
in a Unique Congenital Myopathy
with Prominent Internal Nuclei and Atypical Cores
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Richard A. Manfready,4 Xingli Li,2 Sucheta Joshi,2 Jishu Xu,5 Weiping Peng,5 Alan H. Beggs,4 Jun Z. Li,5
Margit Burmeister,1,5,* and James J. Dowling2,6,*
Congenital myopathies are clinically and genetically heterogeneous diseases that typically present in childhood with hypotonia and
weakness and are most commonly defined by changes observed in muscle biopsy. Approximately 40% of congenital myopathies are
currently genetically unresolved. We identified a family with dominantly inherited congenital myopathy characterized by distal weak-
ness and biopsy changes that included core-like areas and increased internalized nuclei. To identify the causative genetic abnormality in
this family, we performed linkage analysis followed by whole-exome capture and next-generation sequencing. A splice-acceptor variant
in previously uncharacterized CCDC78 was detected in affected individuals and absent in unaffected family members and > 10,000
controls. This variant alters RNA-transcript processing and results in a 222 bp in-frame insertion. CCDC78 is expressed in skeletal
muscle, enriched in the perinuclear region and the triad, and found in intracellular aggregates in patient muscle. Modeling of the
CCDC78 mutation in zebrafish resulted in changes mirroring the human disease that included altered motor function and abnormal
muscle ultrastructure. Using a combination of linkage analysis, next-generation sequencing, and modeling in the zebrafish, we have
identified a CCDC78 mutation associated with a unique myopathy with prominent internal nuclei and atypical cores.Congenital myopathies are a heterogeneous group of
muscle diseases that have a prevalence of approximately
1:26,0001 and are associated with significant disability,
including impaired ambulation, progressive scoliosis, and
chronic respiratory failure, and, in many cases, early
mortality.2 Currently, there are no known treatments or
disease-modifying therapies for these conditions. Congen-
ital myopathies are defined by characteristic changes
observed in diagnostic muscle biopsies, and many cases
can be classified into one of three major subtypes:
core myopathies (central core disease [CCD (MIM
117000)] and multiminicore disease [MIMs 255320 and
602771]),3,4 nemaline myopathies (MIMs 609284,
256030, 161800, 609285, 605355, 609273, and 610687),5
and centronuclear myopathies (CNMs [MIMs 160150,
255200, 614408, and 310400]).6 Although mutations in
14 genes (RYR1 [MIM 180901], ACTA1 [MIM 102610],
NEB [MIM 161650], TPM2 [MIM 190990], TPM3 [MIM
191030], CFL2 [MIM 601443], TNNT1 [MIM 191041],
KBTBD13 [MIM 613727], MTM1 [MIM 300415], DNM2
[MIM 602378], BIN1 [MIM 601248], SEPN1 [MIM
606210], MYH7 [MIM 160760], and MYH3 [MIM
160720]) have been identified as causative in individuals
with these congenital myopathies,7 the genetic basis of
the disease remains unresolved in many affected individ-
uals, and it is currently estimated that these disease genes
account for only approximately 20%–40% of cases.11Molecular & Behavioral Neuroscience Institute, University of Michigan Med
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The AmericIn an effort to define additional genetic causes for
congenital myopathies, we identified a family that had
a novel congenital myopathy with prominent internal
nuclei, atypical cores, and an autosomal-dominant inheri-
tance pattern (Figures 1 and 2). After approval by an insti-
tutional review board, the full clinical history and direct
examination of all five affected members of the three-
generational pedigree (Figure 2A) along with eight unaf-
fected members provided a general overall picture of the
clinical features of the disease in this family. The salient
features of this myopathy include neonatal hypotonia,
distal > proximal weakness, excessive fatigue, prominent
myalgias, mild-to-moderate overall motor impairment
with preserved ambulation, and mild cognitive involve-
ment (see Table S1 available online). Musculature of the
face was not affected, and no affected individuals devel-
oped ophthalmoparesis.
Two diagnostic quadriceps-muscle biopsies were avail-
able for review (Figure 1). The proband’s biopsy (individual
IV.5; biopsy obtained at the age of 5 years) featured marked
type I predominance (85%–90% of fibers; Figures 1D and
S1), fiber-size variability (Figure 1A), excessive central
nuclei (> 30% of fibers; Figure 1B), and core-like areas
(Figures 1E, 1F, and 1I–1L). Immunopositive aggregates
were also revealed with actin and desmin staining (Figures
1G and1H). In addition to frequent central nuclei, ultra-
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Figure 1. Histopathological Features of a Unique Centronuclear Myopathy with Cores
(A) and (B) Hematoxylin and eosin staining highlights mild variation in fiber size (B is a higher magnification). A significant number of
fibers have central nuclei (30%).
(C) Trichrome shows fibers with irregular central staining (*).
(D) Toluidine blue highlights the marked (>90%) type 1 (dark blue) predominance.
(E) and (F) Succinate dehydrogenase (SDH) (E) and combined SDH and cytochrome oxidase (F) reveal type 1 fibers with areas of
central pallor.
(G) and (H) Positive abnormal immunoreactivity for actin (G) and desmin (H).
(I)–(L) Electron microscopy (EM) shows fibers with disorganized sarcomeric architecture (I–L), Z-band streaming (K), and a relative
absence ofmitochondria within the lesions, with increased accumulation ofmitochondria at the periphery (L). Scale bars for EM¼ 2 mm.contractile apparatus, loss of the normal sarcomeric stria-
tion, Z-band streaming, sparse or absent mitochondria in
the center of the lesion with secondary mitochondrial
accumulation at the periphery, and distension of trans-
verse (T)-tubules (Figures 1I–1L). The other biopsy (ob-
tained from individual IV.4 at the age of 10 months)
showed fiber-type variability and increased central nuclei
(15%) as well as desmin and actin immunoreactive aggre-
gates. The overall pathological diagnosis, derived from
the two biopsies, was reported as a congenital myopathy
with prominent internal nuclei, atypical core-like lesions,
and desmin-positive aggregates. On the basis of this path-
ological diagnosis and the dominant inheritance pattern,
mutation analysis was obtained for MTM1, DNM2, and
RYR1 and did not show any abnormalities. Notably, serum
creatine phosphokinase levels were normal.
To determine the genetic basis of disease in this family,
we performed a SNP linkage analysis followed by exome
capture and high-throughput sequencing. Linkage map-366 The American Journal of Human Genetics 91, 365–371, August 1ping was performed on ten individuals (indicated with
an asterisk in Figure 2A) with ~6000-SNP Illumina HL12
linkage panels. Six peaks covering 35 Mbp of genomic
DNA were identified with a LOD score > 1.0 (the range
of scores was 1.4–1.8 with a top LOD score of 1.87 at
rs2301763) (Figure 2B). These linkage areas did not overlap
with any known myopathy genes. Exome capture was
then performed with the NimbleGen SeqCap EZ Exome
Library v1.0 kit (Roche) from one individual and was fol-
lowed by next-generation sequencing with an Illumina Hi-
seq2000 instrument. Initially, identified variants were
filtered such that only those under the linkage peak were
analyzed. A total of 57 variants not found in dbSNP, the
1000 Genomes Project, and the National Heart, Lung,
and Blood Institute (NHLBI) Exome Variant Server mapped
under the linkage peaks. These variants were sorted into
high-, medium-, and low-priority variants by their nature
of variation (missense and splice junction were given the
highest priority) (see Supplemental Subjects and Methods0, 2012
Figure 2. CCDC78 Mutation in a Family with Autosomal-Dominant Centronuclear Myopathy
(A) Pedigree of a family with autosomal-dominant centronuclear myopathy with cores. The index case is indicated with an arrow. Ten
individuals (indicated by *), including five affected individuals, were clinically evaluated and were part of the linkage analysis.
(B) SNP linkage plot showing LOD scores for chromosome 16.
(C) Chromatograph from whole-exome sequencing of the index case indicating a heterozygous C>T change at c.68-1 of CCDC78. The
sequence is in reverse orientation and is thus a G>A change in the canonical splice-acceptor sequence for intron 1.
(D) RT-PCR from lymphoblastoid-cell-derived RNA with the use of CCDC78 exon 1–3-spanning primers. RNA from affected individuals
(PT) reveals the presence of a higher molecular weight band (**) that is barely detectable in RNA from unaffected relatives (CTL).
(E) Sequencing of the upper (**, top chromatogram) and lower (*, bottom chromatogram) bands revealed that the upper band contains
the entire sequence of intron 1. The reference sequence is listed (in black) below each chromatogram, and confirms that the upper band
has intron 1 sequence contiguous with exon 2 sequence. The mutation is detected in the upper band of patient samples only (arrow).
(F) Schematic of the exon-intron structure of the first three exons of CCDC78. Control individuals have normal processing of these
exons, while affected individuals with the CCDC78 mutation have RNA products that do not remove intron 1.for a full description of variant filtering). We tested 13 of
these prioritized variants with the use of Sequenom’s
MassARRAY genotyping analysis in the complete pedigree
and in a panel of 332 unrelated samples. Of these, only one
variant segregated with disease status in the family, was
absent in the control samples, and was not found
in > 10,000 of population samples (Exome Variant Server
from the NHLBI Exome Sequencing Project). This variant
(Figure 2C), which was also confirmed via Sanger se-
quencing, is a heterozygous G>A nucleotide substitution
in the obligatory AG splice acceptor of the second exon
of CCDC78, a previously uncharacterized coiled-coiled-
domain-containing gene located on 16p13 (Gene ID
124093).
The novel sequence variant identified in CCDC78 was
predicted to alter splicing of exon 2. We tested this predic-
tion by analyzing RNA extracted from lymphoblastoid cell
lines from several affected and unaffected members of the
pedigree (Figure 2D). In unaffected individuals, RT-PCR
from exons 1–3 revealed a predominant product of
370 bp as well as a barely detectable product at 500 bp.
Conversely, RT-PCR from affected individuals demon-The Americstrated a significant shift to the higher-molecular-weight
product. Sequencing of both bands revealed that the
smaller band was the expected reference sequence for
exons 1–3; the larger band contained the sequence for
exons 1–3 and, in addition, the entire 222 bp sequence
of intron 1 (Figure 2E). This 222 bp is in-frame with the
coding sequences from exons 1–2 and is predicted to
produce a novel CCDC78 variant with an additional 74
amino acids (Figure 2F). BLAST search analysis of the addi-
tional 222 bp sequence and the resulting 74 novel amino
acids did not identify other RNAs with this product, with
the exception of a single expressed sequence tag
(BC027941).
We performed a preliminary characterization of the
CCDC78 product. Western blot analysis with multitissue
blot demonstrated that CCDC78 is expressed primarily in
skeletal muscle (Figure S2). Immunofluorescence analysis
on cryosections of human skeletal muscle revealed that
CCDC78 staining was found primarily in the perinuclear
region (*), as well as along the sarcolemmal membrane
(arrowheads) and in a reticular pattern within the sarco-
plasm (arrows) (Figure 3A). This reticular pattern partiallyan Journal of Human Genetics 91, 365–371, August 10, 2012 367
Figure 3. Immunolocalization of
CCDC78 in Normal and Patient Skeletal
Muscle
Immunofluorescent analysis of anti-
CCDC78 (red) and anti-RyR1 (green) on
control (upper panels) and patient (lower
panels) skeletal-muscle cryosections.
Upper panels (row A): CCDC78 is found
localized to the sarcolemmal membrane
(arrowheads) and the perinuclear region
(**), as well as in a latticework-type pattern
within the sarcoplasm (arrow). Costaining
with RyR1 reveals that the latticework
pattern corresponds to the triad (arrow),
which is the intersection of the terminal
sarcoplasmic reticulum and the T-tubule.
Lower panels (row B): Immunostaining on
patient muscle reveals aggregates of both
CCDC78 and RyR1 within the sarcoplasm
(arrows).overlapped with a muscle structure called the triad, which
is the intersection of the T-tubule and the terminal sarco-
plasmic reticulum, as demonstrated via coimmunostain-
ing analysis with an antibody to RyR1 (Figure 3A) and to
DHPR1a (Figure S3). RyR1 is a resident protein of the
terminal sarcoplasmic reticulum, is an essential compo-
nent of the excitation-contraction coupling machinery,
and is a cause of both CNM and core myopathy.8 We
next determined the CCDC78 subcellular distribution in
the novel myopathy by performing immunostaining on
patient muscle biopsy sections. In these sections,
CCDC78 was found not only in the areas described for
control muscle but also in large sarcoplasmic aggregates
(Figure 3B). These CCDC78-positive aggregates stained
positive for desmin and actin (Figure 1) and costained
strongly for RyR1 (Figure 3B).
To study the potential effect of the novel variant de-
tected in CCDC78, we modeled (using a protocol approved
by the Institutional Animal Care and Use Committee) the
genetic change using morpholino-mediated splice-site
alteration in the developing zebrafish (see Supplemental
Subjects and Methods). We first identified the zebrafish or-
tholog of CCDC78 (ENSDARG00000030095) by homology
search. This ortholog shares 45% identity at the nucleotide
level with human CCDC78 and has the same predicted
exon-intron structure as the human gene. We designed a
morpholino that targeted the exon 2 splice-acceptor site,
which would be predicted to alter RNA processing in a
manner akin to the sequence variant detected in our
family. This morpholino was injected into 1–2 cell-stage
embryos, and then RNA was extracted at 3 days postfertili-
zation (dpf). RT-PCR analysis revealed three bands: a band
of expected size, a smaller band that was missing exon 2,
and a larger band that included exons 1–3 and the
222 bp of intron 1 (Figure 4A). The larger band was similar
in size and sequence to the altered RNA product detected
from patient lymphoblastoid-cell RNA. Western blot anal-368 The American Journal of Human Genetics 91, 365–371, August 1ysis with anti-CCDC78 of the total protein extracted at
3 dpf showed a band of approximately 50 kDa in samples
from control morphant embryos. ccdc78 morphant
samples, on the other hand, had a reduced amount of
this 50 kDa and the presence of a larger-molecular-weight
product, consistent with altered processing of ccdc78 RNA
(Figure S4).
Embryos injected with ccdc78 morpholino were
analyzed at 1, 2, and 3 dpf. As compared to control-
injected embryos, ccdc78morphants had obvious morpho-
logic and motor deficits, which were most apparent
beginning at 2 dpf. Morphologically, ccdc78 morphants
were smaller and had a shortened body and bent tail
(Figure 4B). In terms of motor behaviors, a range of defects,
from mildly impaired swimming to a complete lack of
movement, were observed on the basis of analysis of the
touch-evoked escape response, a stereotyped behavior
that is prominent at 3 dpf (control versus ccdc78
morphant, Movie S1 versus Movie S2). The majority of
morphant embryos had an at least partially impaired
escape response, and nearly 30% exhibited both no
response and no spontaneous swimming (Figure 4C).
This is suggestive of severe muscle dysfunction.
Muscle from ccdc78 morphants was analyzed for histo-
pathological changes. Light microscopic analysis was per-
formed on isolated myofibers with the use of immunoflu-
orescence (Figure 4D). Myofibers from control embryos
had a CCDC78 expression pattern similar to that seen
in human muscle. Myofibers from ccdc78 morphant
embryos, conversely, had areas of disorganized and irreg-
ular staining of both CCDC78 and RyR1 (arrow) and also
had small aggregates, particularly of CCDC78 (arrow-
heads). Electron-microscopic analysis showed that mor-
phant skeletal muscle had abnormal triad morphology,
with dilated T-tubules and sarcoplasmic reticulum (boxes,
Figure 4E). The muscle also contained numerous areas of
abnormal accumulations of membranous material (arrow),0, 2012
Figure 4. Morpholino-Mediated Alter-
ation of ccdc78 Intron 1 Splicing Results
in Morphological, Behavioral, and Struc-
tural Abnormalities
(A) RT-PCR on RNA from 3 dpf zebrafish
injected with either control morpholino
(CTL) or increasing concentrations of
ccdc78 morpholino (in mM). RT-PCR
with primers from exons 1–3 of ccdc78
demonstrate that the morpholino inhibits
proper splicing of intron 1/exon 2. The
most prominent change is the presence
of a higher molecular band that was
confirmed to contain exons 1–3 and all
of intron 1 (arrow). RT-PCR with actin
primers was done for verification of RNA
integrity.
(B) ccdc78morphants are morphologically
abnormal, having bent backs and fore-
shortened tails.
(C) ccdc78 morphants had abnormal
motor behavior. Depicted is a graph of
the touch-evoked escape response (see
also Movies S1 and S2). A total of
73.1% 5 3.9% of ccdc78 morphants (as
opposed to 10.3%5 3.5% of control mor-
phants) had an abnormal touch-evoked
escape response (n ¼ 9 independently in-
jected clutches, and a minimum of 20
embryos were assessed per clutch). MO,
morpholino.
(D) Immunostaining was performed on isolated myofibers from 3 dpf control (CTL) and ccdc78 morphants. Left panels show anti-
CCDC78 staining. CTL morpholino (MO) myofibers had a staining pattern similar to that seen in human skeletal muscle, with locali-
zation to the membrane and the perinuclear region (nuclei in blue), as well as more faintly to the triad. ccdc78 MO myofibers had
aberrantly aggregated clusters of CCDC78 (arrowheads). Right panels show anti-RyR1 staining. CTLMOmyofibers had a normal pattern
of staining, whereas ccdc78 MO myofibers had disorganized areas of RyR1 staining that included small aggregates (arrow).
(E) Electron-microscopic analysis of 3 dpf morphant zebrafish. As compared to control muscle fibers (CTL MO, left panel), muscle from
ccdc78 morphants had dilated terminal sarcoplasmic reticulum (boxes, middle panel). In addition, whirls of redundant membranes
(arrow) and areas of dilated and swollen sarcoplasmic reticulum (**) were frequently seen throughout the skeletal muscle of ccdc78
morphants and were never observed in controls (n ¼ 3 embryos examined). Scale bar for left and center panels: 500 nm. Scale bar
for right panel: 2 mm.as well as pools of swollen sarcoplasmic reticulum (**)
(Figure 4E).
To determine whether CCDC78 mutations were a
common cause of congenital myopathies, we evaluated
46 additional unrelated probands (25 by conventional
Sanger sequencing and 21 by analysis of the CCDC78 locus
in whole-exome data sets). This cohort included 30 cases
that had clinicopathological diagnoses of CNM, 6 that
had congenital fiber-type disproportion, and 10 that had
undefined forms of congenital myopathy characterized
by typical clinical presentations and nonspecific (but non-
dystrophic) findings in the muscle biopsy. None of these
individuals harbored CCDC78 variants that met the
filtering criteria described above, suggesting that CCDC78
mutations are a rare cause of these myopathies. Of note,
none of the cases analyzed had any form of core myopathy
(typical or atypical).
In summary, using a combination of linkage analysis,
next-generation sequencing, and mutation modeling in
the zebrafish, we identified and subsequently validated
a novel mutation in a previously uncharacterized gene
associated with a unique autosomal-dominant congenital
myopathy with prominent internal nuclei and atypicalThe Americcores. On the basis of its histopathology, this myopathy
most resembles that described in a recently reported series
of cases caused by recessive RYR1 mutations,9 though it
also shares some more general features with other CNMs.
RYR1 mutations can be associated with both increased
central nuclei and the presence of core-like structures
and are probably one of the most common causes of
congenital myopathies, accounting for as many as 32%
of CNM cases.6,10 Other previously identified genetic
causes of CNMs include mutations in MTM1, DNM2,
and BIN1. Although the pathogenic mechanism(s) respon-
sible for the presence of excessive central nuclei are
still unknown, recent studies have identified abnormal
excitation-contraction coupling and impaired calcium
homeostasis as common aspects of the disease pathogen-
esis.11–16 Current research is focused on determining how
mutations in these gene products resulted in the observed
alterations in muscle structure and function, and much
remains to be understood about this untreatable and clin-
ically important myopathy subtype.
The identification of a CCDC78 mutation in a family
with congenital myopathy is an important step in terms
of bridging the knowledge gap for these disorders, relatedan Journal of Human Genetics 91, 365–371, August 10, 2012 369
to both diagnostic assessment and understanding of the
disease pathogenesis. A substantial portion of congenital
myopathies are genetically unresolved,6 and CCDC78
now represents an excellent new candidate gene for indi-
viduals without an identified gene mutation. In particular,
CCDC78 may be considered in cases wherein muscle
biopsy reveals frequent internal nuclei and/or core-like
areas. Future studies are needed to address the possibility
of a larger association between CCDC78 mutation and
individuals who have congenital myopathies without
a known genetic cause. Notably, however, our initial exam-
ination suggests that it is unlikely to be a frequent cause of
classic CNM.
Another important aspect of this study is the identifica-
tion of CCDC78, a previously uncharacterized protein, as
a gene product of potential importance for the regulation
of essential muscle function(s). Our initial analyses,
encompassing immunofluorescence studies and morpho-
lino-mediated splice-site alteration in the zebrafish, point
to a potential function for CCDC78 in the regulation of
the structure and function of the triad, the subcellular
structure within the muscle containing RyR1 and
disturbed in all previously characterized forms of
CNM.11,13 Given that interplay between RyR1, the other
known causes of CNM, and the regulation of excitation-
contraction coupling is still uncertain, the uncovering of
CCDC78 offers the potential for significant advancement
in the understanding of this disease process. Future studies
are needed for further delineation of these exciting poten-
tial function(s) of CCDC78 in the skeletal muscle and
at the triad.
Our study also has broader implications for gene
discovery via next-generation sequencing. One of the
key challenges in the application of next-generation
sequencing to rare, monogenetic diseases is the assessment
of novel variants.17 In this study, we illustrated the use of
the zebrafish for testing the pathogenicity of sequence
variants found via whole-exome sequencing. In particular,
through the use of morpholino technology, we were able
to recapitulate in zebrafish the genetic change observed
in the affected individuals, and we then were able to
identify some of the specific histopathological changes
observed in their muscle biopsies. The demonstration of
these pathological changes in the zebrafish model thus
lends significant validity to the proposed pathogenicity
of the identified variant. This approach is excellently
suited for the study of congenital myopathies, wherein
the conditions are largely defined by classic histopatholog-
ical changes, and wherein previously published zebrafish
models have been shown to recapitulate these features. It
can also be applied to a range of human diseases that are
currently under evaluation via whole-exome and whole-
genome analysis, and it would be particularly well adapted
for diseases wherein observable and characteristic histo-
pathological changes are described. This is supported by
recent publications wherein whole-exome sequencing
and zebrafish modeling were used for gene discovery in370 The American Journal of Human Genetics 91, 365–371, August 1retinal-renal ciliopathy,17–20 dilated cardiomyopathy, and
retinitis pigmentosa.Supplemental Data
Supplemental Data include four figures, one table, two movies,
and Supplemental Subjects and Methods and can be found with
this article online at http://www.cell.com/AJHG/.Acknowledgments
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